Introduction
============

Hepatocellular carcinoma (HCC) is the most common human liver malignancy. Worldwide, the estimated number of mortalities caused by HCC is \~810,000 per year, while the estimated number of new cases of HCC is \~854,000 per year ([@b1-ol-0-0-11931]). As a nation with a large population and high prevalence of hepatitis B virus (HBV) and HCV, China accounts for \~422,100/year of total HCC mortalities worldwide ([@b2-ol-0-0-11931]). Thus, the mortality and severity of HCC represent an urgent health problem in China.

Current management of HCC includes potentially curative surgical resection and non-surgical therapeutics, such as radiofrequency ablation, percutaneous ethanol injection and trans-arterial embolization ([@b3-ol-0-0-11931]). Moreover, combined chemotherapy and recently developed immunotherapies constitute the treatment of patients with advanced HCC ([@b3-ol-0-0-11931]). However, it remains difficult to predict overall survival (OS) of patients with HCC for treatment selection. Tumor classification systems, such as TNM, Okuda, Cancer of the Liver Italian Program and Barcelona Clinic Liver Cancer, have been widely used for prognostic assessment ([@b4-ol-0-0-11931],[@b5-ol-0-0-11931]). However, due to the heterogeneity of malignancies, there is still no consensus on the most appropriate staging system for predicting the survival of patients with HCC ([@b6-ol-0-0-11931],[@b7-ol-0-0-11931]). Previous studies have been conducted to identify potential biomarkers. It has been revealed that frequently used biomarkers, such as α-fetoprotein (AFP) ([@b8-ol-0-0-11931]) and carbohydrate antigen 19-9 (CA19-9) ([@b9-ol-0-0-11931]), have a relatively poor performance as predictors of long-term outcome.

Recently, there have been studies on the mechanism of 5′-nucleotidase domain containing 2 (*NT5DC2*) in some malignancies, including gliomas ([@b10-ol-0-0-11931]) and liver cancer types ([@b11-ol-0-0-11931]). *NT5DC2* has been reported to be associated with certain types of mental disorders, including schizophrenia, attention deficit hyperactivity disorder ([@b12-ol-0-0-11931],[@b13-ol-0-0-11931]) and borderline personality disorders ([@b14-ol-0-0-11931]). *NT5DC2* promotes tumorigenesis of glioma stem-like cells by inducing the expression of FYN proto-oncogene (Fyn) ([@b10-ol-0-0-11931]), as well as increases tumor cell proliferation in HCC by stabilizing epidermal growth factor receptor ([@b11-ol-0-0-11931]). Currently, to the best of our knowledge, there is no research focusing on the value of *NT5DC2* in the prognosis of HCC.

The present study aimed to investigate the suitability of *NT5DC2* as a novel prognostic predictor for HCC.

Materials and methods
=====================

### Data source

The latest liver cancer (LIHC) project data, including Level 3 RNA sequencing (RNA-seq) data and clinical data, were obtained using the R package, TCGAbiolinks v2.16.0 ([@b15-ol-0-0-11931]), as an independent validation cohort. There were 377 cases available including 255 males and 122 females. The age range was between 16 to 90, with a median of 61. mRNA gene expression levels are presented as a normalized value of level 3 RNA-seq data. Then, *NT5DC2* mRNA expression was compared between cancerous and paracancerous tissues. In HCC samples, patients were assigned into two equal groups (*NT5DC2*-High and *NT5DC2*-Low) based on the median normalized value of *NT5DC2*. The reciprocal The Cancer Genome Atlas (TCGA) clinical data (updated on 2019/08/08), comprising age, sex, weight, Child-Pugh score ([@b16-ol-0-0-11931]), TNM stage ([@b17-ol-0-0-11931]), residual tumor, Edmondson grade ([@b18-ol-0-0-11931]), relapse-free survival (RFS) and OS, were collected for further statistical analysis.

The Sequence Read Archive (SRA) dataset, SRP174991, including paired HCC sample RNA-seq raw data ([@b19-ol-0-0-11931]), were downloaded using the Linux package, prefetch (included in the Sra-tools version 2.10.6, <http://github.com/ncbi/sra-tools>).

### Sample and clinical data collection

Patients diagnosed with HCC, receiving surgical resection between January 2008 and December 2015, in the Department of Hepatology and the Department of General Surgery, Peking Union Medical College Hospital (PUMCH), were retrospectively enrolled in this study. There were 134 cases available including 114 males and 20 females. The age range was between 32 to 82 years, with a median of 56 years. The reciprocal clinical data including age, sex, surface antigen of the hepatitis B virus (HBsAg), Anti-hepatitis C (HCV), aspartate transaminase, alanine aminotransferase (ALT), γ-glutamyl transpeptidase (GGT), alkaline phosphatase, AFP, CA19-9, TNM stage and Edmonson grade, were obtained via the Hospital Information System in PUMCH. The OS of enrolled patients was assessed via phone calls and routine clinical follow-up. This project was approved by the Ethic Committee, Peking Union Medical College Hospital (approval no. JS-1569) and had been performed in accordance with Declaration of Helsinki and its later amendments. Written informed consent was provided by all patients before surgery.

### RNA extraction and reverse transcription-quantitative PCR (RT-qPCR)

Paired HCC samples, which were preserved frozen samples obtained during surgery, used in RT-qPCR were randomly chosen from the PUMCH cohort. Samples from patients with HCC were preserved in liquid nitrogen (−196°C) immediately after resection.

Total RNA was extracted from liquid nitrogen-preserving tissues using TRIzol^®^ reagent (Invitrogen; Thermo Fisher Scientific, Inc.) with Phasemaker^™^ tubes (Invitrogen; Thermo Fisher Scientific, Inc.), according to manufacturer\'s protocol. RT was performed using the GoScript™ RT system (Promega Corporation) with oligo-dT ([@b15-ol-0-0-11931]) primer at 42°C for 1 h, according to the manufacturer\'s instructions. RT-qPCR was performed with 2X GoTaq Master Mix (cat. no. A6001; Promega Corporation) using an Applied Biosystems™ 7500 Fast Dx Real-Time PCR System (Thermo Fisher Scientific, Inc.). Thermocycling conditions: 95°C for 2 min, 40 cycles: 95°C for 10 sec, 60°C for 30 sec. *NT5DC2* mRNA expression was normalized to *GAPDH* mRNA expression. The gene expression was calculated via 2^−ΔΔCq^ method ([@b20-ol-0-0-11931]). The primers validated for amplification efficiency and selected for RT-qPCR were as follows: *NT5DC2* forward (F), 5′-GCAGCCATCTACGCCAACA-3′ and reverse (R), 5′-TCACGGGCGGTACTGAAGA-3′; and *GAPDH* F, 5′-GGAGCGAGATCCCTCCAAAAT-3′ and R, 5′-GGCTGTTGTCATACTTCTCATGG-3′.

### Haemotoxylin-eosin (H&E) and immunohistochemical (IHC) staining of tissue microarrays (TMAs)

TMAs were constructed from formalin-fixed, paraffin embedded tissue blocks stored at the Department of Pathology, PUMCH. All specimens were previously fixed in 10% neutral formalin solution at room temperature for 12 h before paraffin embedded. Tissue blocks of paired cancer, paracancerous tissue and randomly selected healthy tissue, as previously established by pathologists, were selected and TMAs were prepared. Tissue cores were re-embedded in paraffin, resected into 8-µm thick slides. HE staining was performed using Gemini AS Automated Slide Stainer (Thermo Fisher Scientific, Inc.) with a normal H&E staining program in room temperature. IHC staining was performed with HIER pH 6 retrieval. Slides were blocked by normal goat serum working solution (cat. no. SP-9001; OriGene Technologies, Inc.) at room temperature for 15 min, then added 100 µl Anti-*NT5DC2* rabbit polyclonal antibody (1:50; cat. no. NBP2-13679; Novus Biologicals, LLC), and incubated at 37°C for 60 min. Then, 100 µl biotin-labeled goat anti-rabbit polyclonal antibody solution (ready to use; cat. no. SP-9001; OriGene Technologies, Inc.) was added to slides and incubated at room temperature for 15 min. The reactions were visualized by diaminobenzidine (DAB) for 30 sec at room temperature and counterstained with hematoxylin for 10 sec at room temperature. Normal goat serum working solution, biotin-labeled goat anti-rabbit polyclonal antibody solution and streptavidin-HRP reagent were included in the SPlink Biotin-Streptavidin-horseradish peroxidase (HRP) Detection kit (cat. no. SP-9001; OriGene Technologies, Inc.). 1X DAB was diluted from the 20X DAB kit (cat. no. ZLI-9017; OriGene Technologies, Inc.). Sample results were evaluated by pathologists under a light microscope at the PUMCH. IHC-TMA slides were scanned using Panaroma SCAN II (3DHISTech Ltd.). In total, three random ×400 fields of view of the IHC chips were captured for mean optical density (MOD) analysis via ImageJ 1.52 (National Institutes of Health). The MOD was calculated as follows: MOD=Integrated OD/Sum area of samples. MODs were compared between cancerous tissues, para-HCC tissues and distal healthy liver tissues in IHC TMAs, and reciprocal receiver operating characteristic (ROC) curves were generated.

### Statistical analysis

All experiments were repeated three times. P\<0.05 was considered to indicate a statistically significant difference. Quantitative analyses were performed using a Kolmogorov-Smirnov test for normality of the distribution and an F-test for equality of variances. Samples with normal distribution were represented as mean ± SD, while samples with non-normal distribution were represented as median (interquartile range). Categorical samples were expressed as n% (n). Moreover, two groups with normal distribution were compared via Student\'s t-test; two paired groups with normal distribution were compared using paired t-test. Multiple groups with normal distribution were compared using one-way ANOVA test followed by Tukey\'s post hoc test. Groups with non-normal distribution were compared using Mann-Whitney U test. Fisher\'s exact test and χ^2^ test were used for comparison of categorical data. Kaplan-Meier survival analyses and Rényi tests were performed between *NT5DC2*-High and *NT5DC2*-Low groups. ROC curve was used to assess the diagnostic value of *NT5DC2* in IHC TMAs. The median cut-off value was selected according to ROC curve.

Univariate Cox proportional hazards regression and multivariate Cox proportional hazards regression models were applied to analyze the impact of potentially confounding factors on OS. Potential confounding factors in both groups were evaluated via a univariate Cox regression model. Potentially significant factors (P\<0.1) in the univariate Cox regression model were included in a multivariate Cox regression model. The hazard ratio (HR), 95% CI and statistical significance are presented in the tables. All statistical analyses were performed via R software 3.5.3 ([@b21-ol-0-0-11931]).

### Bioinformatic analyses

To investigate *NT5DC2* function in patients with HCC, an integrative analysis of *NT5DC2* was performed. Patients of the LIHC dataset were categorized into two groups according to *NT5DC2* expression: *NT5DC2*-Low and *NT5DC2*-High. Gene Set Enrichment Analysis (GSEA) was performed using GSEA version 4.0.1 with MSigDB 7.0 ([@b22-ol-0-0-11931],[@b23-ol-0-0-11931]). Gene sets with significant enrichment were listed, and RNA-seq data from the SRA dataset were mapped to the reference genome using hisat2 v2.1.0 ([@b24-ol-0-0-11931]). The reads were processed with featureCounts v1.6.0 ([@b25-ol-0-0-11931]) and DESeq2 v1.24.0 ([@b26-ol-0-0-11931]). The references consisted of the human reference genome (GRCh38) and the Ensembl annotated human transcriptome (GRCh38.v98). Normalized values were compared between the two groups and *NT5DC2* expression levels were analyzed using the R package, ggplot2 v3.2.1 (<https://ggplot2.tidyverse.org/>). A Kaplan-Meier survival curve was generated using the R packages, survival v2.44-1.1 (<https://CRAN.R-project.org/package=survival>) and survminer v0.4.6 (<https://rpkgs.datanovia.com/survminer/index.html>).

Results
=======

### NT5DC2 mRNA is upregulated in cancerous tissue compared with paracancerous tissue in multiple datasets

In the LIHC dataset of TCGA, 377 cases were available, but eight cases were excluded due to the lack of RNA-seq data. Moreover, 10 cases of non-HCC liver cancer were excluded. One case was excluded due to the lack of OS data. Finally, 358 patients, for whom survival data were available, were included in the analysis. A total of 358 HCC tissues and 40 para-HCC tissues were examined. Normalized NT5DC2 expression was significantly upregulated in 358 HCC tissues compared with the para-HCC tissues (P\<0.0001; [Fig. 1A](#f1-ol-0-0-11931){ref-type="fig"}). The available paired samples were selected (n=50) in TCGA LIHC dataset, and a ROC curve analysis was performed. The area under the curve (AUC) of paired HCC samples was 0.942 ([Fig. 1B](#f1-ol-0-0-11931){ref-type="fig"}).

In the SRP174991 dataset, *NT5DC2* expression was compared in 35 pairs of HCC and para-HCC samples from patients with HBV-related HCC. The results demonstrated a significant upregulation of *NT5DC2* in HCC tissues (P\<0.0001; [Fig. 1C](#f1-ol-0-0-11931){ref-type="fig"}). In the 35 paired HCC SRP174991 samples, the AUC of paired HCC samples was 0.810 ([Fig. 1D](#f1-ol-0-0-11931){ref-type="fig"}).

*NT5DC2* mRNA expression was examined using RT-qPCR in 44 HCC tissues and 44 para-HCC tissues randomly selected from the PUMCH cohort. The mRNA expression of NT5DC2 was significantly higher in cancerous compared with paracancerous tissues (P\<0.05; [Fig. 1E](#f1-ol-0-0-11931){ref-type="fig"}). ROC curve analysis was performed and the AUC was 0.637 ([Fig. 1F](#f1-ol-0-0-11931){ref-type="fig"}).

IHC was conducted to analyze a TMA comprising 38 randomly selected non-HCC liver tissues, 32 paracancerous liver tissues and 32 HCC liver tissues ([Fig. 1G](#f1-ol-0-0-11931){ref-type="fig"}). IHC staining identified a higher expression of *NT5DC2* in HCC tissues compared with both para-HCC tissues (P\<0.05) and distal healthy liver tissues (P\<0.0001; [Fig. 1H](#f1-ol-0-0-11931){ref-type="fig"}). Furthermore, ROC curves of *NT5DC2* expression in HCC and para-HCC tissues were generated, and the AUC of *NT5DC2* was 0.734 ([Fig. 1I](#f1-ol-0-0-11931){ref-type="fig"}).

### NT5DC2 gene upregulation reduces OS and RFS in patients with HCC

In the LIHC cohort of TCGA, 358 patients with available survival data were included in the survival analysis. These patients were categorized into two groups based on the median value of *NT5DC2* expression: *NT5DC2*-High (n=179) and *NT5DC2*-Low (n=179). The baseline data of the two groups are listed in [Table I](#tI-ol-0-0-11931){ref-type="table"}. Kaplan-Meier and Rényi analysis results demonstrated significant differences in OS (P=0.030; [Fig. 2A](#f2-ol-0-0-11931){ref-type="fig"}) and RFS (P=0.024; [Fig. 2B](#f2-ol-0-0-11931){ref-type="fig"}).

In the PUMCH cohort, a total of 134 patients were diagnosed with HCC and received surgical therapy ([Table II](#tII-ol-0-0-11931){ref-type="table"}). These patients were retrospectively enrolled in this study and categorized into two groups according to the median IHC MOD: *NT5DC2*-High (n=67) and *NT5DC2*-Low (n=67). Kaplan-Meier analysis was performed, and the Rényi test indicated that patients in the *NT5DC2*-High group had a significantly poorer OS (P=0.039) compared with the *NT5DC2*-Low group ([Fig. 2C](#f2-ol-0-0-11931){ref-type="fig"}).

### NT5DC2 gene upregulation is a risk factor associated with poor OS and RFS

In TCGA LIHC cohort, 358 patients with available survival data were categorized into two groups based on the median value of *NT5DC2* expression: *NT5DC2*-High (n=179) and *NT5DC2*-Low (n=179). It was found that the two groups were different in age (P=0.013), weight (P=0.003), TNM stage (P\<0.001) and Edmondson grade (P=0.026; [Table I](#tI-ol-0-0-11931){ref-type="table"}).

To exclude potential confounding biases, clinically significant variables, such as age, sex, *NT5DC2*/1,000 units (*NT5DC2*/1,000), TNM stage and Edmondson grade were included in univariate Cox proportional hazards regression models to evaluate their influence on OS. The results suggested that both *NT5DC2*/1,000 (P=0.001; HR=2.227; 95% CI=1.369-3.625) and TNM stage (P\<0.001; HR=1.512; 95% CI=1.284-1.781) were risk factors associated with reduced OS ([Table II](#tII-ol-0-0-11931){ref-type="table"}). These potential risk factors were included in a multivariate Cox proportional hazards regression model, which indicated that *NT5DC2*/1,000 (P=0.043; HR=1.695; 95% CI=1.016-1.727) and TNM stage (P\<0.001; HR=1.460; 95% CI=1.235-1.727) were independent risk factors for reduced OS ([Table II](#tII-ol-0-0-11931){ref-type="table"}).

Age, sex and TNM stage were also included in univariate Cox proportional hazards regression models to evaluate the impact of these factors on RFS. The results demonstrated that *NT5DC2*/1,000 (P*\<*0.001; HR=2.360; 95% CI=1.547-3.599) and TNM stage (P\<0.001; HR=1.515; 95% CI=1.312-1.750) were risk factors for shorter RFS ([Table III](#tIII-ol-0-0-11931){ref-type="table"}). These potential risk factors were included in a multivariate Cox proportional hazards regression model, which identified that the *NT5DC2*/1,000 (P*=*0.011; HR=1.780; 95% CI=1.143-2.772) and TNM stage (P\<0.001; HR=1.444; 95% CI=1.242-1.678) was independent risk factors for reduced RFS ([Table III](#tIII-ol-0-0-11931){ref-type="table"}).

In the PUMCH dataset, multiple factors, including ALT, GGT and CA19-9, significantly differed between *NT5DC2*-High and *NT5DC2*-Low groups ([Table IV](#tIV-ol-0-0-11931){ref-type="table"}). These potential risk factors, age, sex, *NT5DC2*-IHC MOD/10 units (*NT5DC2*/10), TNM stage, AFP per 1,000 units (AFP/1,000) and HBsAg were individually included in univariate Cox proportional hazards regression model. Univariate Cox regression models suggested that *NT5DC2*/10 (P=0.002; HR=1.185; 95% CI=1.064-1.320), AFP/1,000 (P\<0.001; HR=1.017; 95% CI=1.007-1.026) and TNM stage (P\<0.001; HR=1.703; 95% CI=1.338-2.168) were risk factors for poor OS ([Table V](#tV-ol-0-0-11931){ref-type="table"}). Potential risk factors were included in a multivariate Cox proportional hazards regression model, indicating that *NT5DC2*/10 (P\<0.001; HR=1.219; 95% CI=1.090-1.364) and TNM stage (P\<0.001; HR=1.830; 95% CI=1.409-2.377) were independent risk factors for poor OS ([Table V](#tV-ol-0-0-11931){ref-type="table"}).

### NT5DC2 may participate in cancer-related biological processes in HCC

GSEA was performed in TCGA LIHC cohort. Gene expression data of TCGA LIHC cohort were divided into two groups based on normalized *NT5DC2* gene expression: *NT5DC2*-High and *NT5DC2*-Low. GSEA was performed based on the phenotype of the group ([Fig. 3B](#f3-ol-0-0-11931){ref-type="fig"}). In cancer-related phenotype, a liver cancer survival related gene set, LEE_LIVER_CANCER_SURVIVAL_UP, and a metastasis-related gene set, LIAO_METASTASIS, were enriched. Moreover, a proliferation-related gene set was enriched, CHIANG_LIVER_CANCER_SUBCLASS_PROLIFERATION_UP. It was suggested that the bile acid may be downregulated, since the bile acid metabolism-related gene set was also enriched, HALLMARK_BILE_ACID_METABOLISM.

Mechanically, two Cyclin-Rb-E2F pathway related gene sets, REN_BOUND_BY_E2F and LEE_LIVER_CANCER_MYC_E2F1_DN, were significantly enriched. In addition, SARRIO_EPITHELIAL_MESENCHYMAL_TRANSITION_UP, as an epithelial-mesenchymal-transition (EMT)-related gene set, was upregulated. Gene set YAMASHITA_LIVER_CANCER_STEM_CELL_DN, which was related to liver cancer stem-like cells, was also enriched. The plot of GSEA enrichment is presented in [Fig. 3](#f3-ol-0-0-11931){ref-type="fig"}.

Discussion
==========

Reliable biomarkers may aid in the correct clinical decisions by surgeons when in dilemma over diagnosis ([@b27-ol-0-0-11931]). Most traditional markers of HCC are suitable for early diagnosis. However, commonly used biomarkers, such as AFP ([@b28-ol-0-0-11931]), carcinoembryonic antigen ([@b29-ol-0-0-11931]) and CA19-9 ([@b30-ol-0-0-11931]), have shown poor performance in HCC prognosis before surgery. The present study demonstrated that the evaluation of *NT5DC2* expression via IHC staining and RNA-seq, but not RT-qPCR, was capable of distinguishing HCC tissues from paired para-HCC tissues. In the current study, RT-qPCR exhibited the lowest AUC, suggesting its unsuitability for clinical use. RNA-seq of HCC and para-HCC tissues resulted in a higher AUC compared with IHC staining. However, IHC staining is cheaper and simpler compared with RNA-seq, and the analysis is easily performed, especially in bioptic samples ([@b31-ol-0-0-11931]).

The present results suggested that *NT5DC2* was a potential predictor of OS, although in TCGA LIHC cohort, the Rényi P-value was initially not significant. Notably, in this cohort, OS referred to all-cause mortality. It was identified that, in this cohort, the average age of enrolled patients at diagnosis was \~60 years. Therefore, long-term follow-up could exceed the life expectancy of enrolled patients. HCC has a comparatively low 5-year survival rate ([@b32-ol-0-0-11931]); therefore, an endpoint of follow-up was set up as the 5th year. Then, the Rényi P-value became significant. In the multivariate Cox regression model, *NT5DC2* was an independent risk factor for reduced OS and RFS, indicating that it was a potential prognostic factor for HCC. This Cox regression model also demonstrated that the TNM stage was associated with both OS and RFS, in accordance with previous studies ([@b33-ol-0-0-11931]--[@b35-ol-0-0-11931]).

In the current study it was identified that whether IHC or RNA-sequencing were used, *NT5DC2* could be a beneficial indicator of the prognosis of HCC. TNM stage and *NT5DC2* were found to be independent risk factors; hence, *NT5DC2* can increase the prognostic value of the TNM stage. As a common method of pathological diagnosis, the accessibility of IHC is not inferior to serum biomarkers such as AFP ([@b27-ol-0-0-11931]). However, the present results indicated that AFP was a risk factor dependent on TNM stage. A previous study has shown that the increase in serum AFP levels was related to the tumor volume of HCC ([@b36-ol-0-0-11931]). Since TNM stage already contains the tumor volume, the prognostic value of AFP may be limited, especially when used simultaneously with the TNM stage ([@b37-ol-0-0-11931]). Therefore, *NT5DC2* is more suitable as a supplement to TNM stage compared with AFP.

In the present study, GSEA analysis in *NT5DC2*-High and *NT5DC2*-Low groups, and it was found that *NT5DC2* upregulation was associated with metastasis and survival, which was in accordance with the Kaplan-Meier analyses results. While the detailed mechanism of how *NT5DC2* upregulation affects OS and RFS in patients with HCC remains elusive, the GSEA result may provide some suggestions. For example, the enriched gene set included REN_BOUND_BY_E2F, a gene set of E2F bound targets, which was a result of Anti-E2F chromatin immunoprecipitation and sequencing in mammal cell-lines ([@b38-ol-0-0-11931]). Thus, *NT5DC2* upregulation could reflect Cyclin-retinoblastoma tumor suppressor (Rb)-E2F pathway activation ([@b39-ol-0-0-11931]). Elevated E2F or E2F target expression is associated with poor HCC prognosis ([@b40-ol-0-0-11931],[@b41-ol-0-0-11931]). In a previous study of HCC, overexpression of *NT5DC2* significantly promoted the change of cell cycle from G~1~ to S phase and the expression of cyclins was upregulated ([@b11-ol-0-0-11931]). The Rb-E2F pathway is an important G~1~/S phase checkpoint, and the G~1~/S ratio change that occurs during *NT5DC2* overexpression is likely due to the Cyclin-Rb-E2F pathway, but this requires further verification ([@b39-ol-0-0-11931]).

An enrichment in EMT-related genes was also identified in the current study, which was consistent with a previous report ([@b42-ol-0-0-11931]). EMT is a strong clinical indicator for HCC, and is crucial for HCC metastasis ([@b42-ol-0-0-11931]). It has been shown that transforming growth factor-β-induced EMT may also induce a stemness phenotype in HCC cell-lines ([@b43-ol-0-0-11931]). In glioma stem-like cells, NT5DC2 was revealed to be highly expressed and induce the upregulation of Fyn, resulting in an aggressive phenotype ([@b10-ol-0-0-11931]). Moreover, in the current study, the cancer stem cell-related dataset, YAMASHITA_LIVER_CANCER_STEM_CELL_DN_96, was enriched in association with *NT5DC2* expression, as assessed using GSEA. However, the molecular mechanism via which *NT5DC2* influences HCC stemness requires further investigation.

A strength of the current study was that the role of *NT5DC2* as a risk factor for OS was demonstrated in two independent HCC cohorts. However, this study has some limitations. First, in the PUMCH cohort, \>70% of patients with HCC were HBV- or HCV-positive. Thus, the results of IHC-stained TMA may not apply to patients from Western countries, where HBV/HCV infection rates are much lower ([@b44-ol-0-0-11931]). Second, this study did not demonstrate *NT5DC2* suitability as a serum biomarker, possibly representing a limitation to its clinical use. However, since previous IHC analysis of multiple biomarkers, including human epidermal growth factor receptor 2F ([@b45-ol-0-0-11931]) and programmed death-ligand 1 ([@b46-ol-0-0-11931]), was highly consistent between surgical resection samples and bioptic samples, IHC staining may still be a suitable method for the analysis of bioptic samples.

Overall, the present study demonstrated the value of NT5DC2 as an prognostic biomarker in multiple HCC cohorts. In the multivariate Cox regression model, NT5DC2 upregulation was an independent risk factor of poor OS in both cohorts and poor RFS in LIHC cohort. GSEA indicated the enrichment of a series of survival- and metastasis-related gene-sets, such as LEE_LIVER_CANCER_SURVIVAL_UP and LIAO_METASTASIS.
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![*NT5DC2* is upregulated in cancerous tissue compared with paracancerous tissue in multiple datasets. (A) Violin plot of the difference in *NT5DC2* expression value between HCC and paired para-HCC samples in TCGA LIHC cohort. (B) ROC curve of *NT5DC2* expression in distinguishing between HCC and paired para-HCC tissues in TCGA LIHC cohort. The AUC was calculated and illustrated. (C) Violin plot of the difference in *NT5DC2* expression value between HCC and paired para-HCC samples in SRP174991. (D) ROC curve of *NT5DC2* expression for distinguishing between HCC and paired para-HCC tissues in SRP174991. AUC was calculated and illustrated. (E) Violin plot of the difference in *NT5DC2* expression between HCC and paired para-HCC samples in selected HCC and paired para-HCC samples using reverse transcription-quantitative PCR. (F) ROC curve of *NT5DC2* expression for distinguishing between HCC and paired para-HCC tissues in SRP174991. AUC was calculated and illustrated. (G) Selected tissue specimens in TMA of HCC, para-HCC and healthy liver samples stained using H&E or IHC. (H) Violin plot demonstrating the difference in *NT5DC2* expression between HCC and paired para-HCC samples in a TMA of the PUMCH cohort. Expression between groups were compared using one-way ANOVA followed by Tukey\'s test. (I) ROC curve of *NT5DC2* expression for distinguishing between HCC and paired para-HCC tissues in IHC-TMA of HCC, para-HCC and healthy liver samples. AUC was calculated and illustrated. \*P\<0.05, \*\*\*\*P\<0.0001. ROC, receiver operating characteristic; AUC, area under the curve; *NT5DC2*, 5′-nucleotidase domain containing 2; HCC, hepatocellular carcinoma; TCGA, The Cancer Genome Atlas; LIHC, liver cancer; TMA, tissue microarray; H&E, hematoxylin and eosin; IHC, immunohistochemistry; PUMCH, Peking Union Medical College Hospital; CA, cancer; PARA, paracancerous.](ol-20-04-11931-g00){#f1-ol-0-0-11931}

![*NT5DC2* gene upregulation reduces OS and RFS in patients with HCC. (A) Kaplan-Meier curve of time to all-cause mortality over 5 years in TCGA LIHC cohort. (B) Kaplan-Meier curve of time to tumor recurrence over 10 years in TCGA LIHC cohort. (C) Kaplan-Meier curve of time to all-cause mortality over 7 years in the PUMCH cohort. OS, overall survival; RFS, relapse-free survival; *NT5DC2*, 5′-nucleotidase domain containing 2; HCC, hepatocellular carcinoma; CA, cancer; PARA, paracancerous; TCGA, The Cancer Genome Atlas; LIHC, liver cancer; PUMCH, Peking Union Medical College Hospital.](ol-20-04-11931-g01){#f2-ol-0-0-11931}

![*NT5DC2* may participate in cancer-related biological processes in HCC. Gene Set Enrichment Analysis demonstrated the enrichment score of multiple cancer-related pathways in *NT5DC2*-overexpressing patients in The Cancer Genome Atlas liver cancer cohort. In the bottom, the left side of this list (red color) contains genes upregulated in the gene set. The right side of the list (blue color) contains downregulated genes in the gene set. HCC, hepatocellular carcinoma.](ol-20-04-11931-g02){#f3-ol-0-0-11931}

###### 

Baseline characteristics of TCGA LIHC dataset (n=358).

  Characteristic     *NT5DC2*-High   *NT5DC2*-Low    P-value
  ------------------ --------------- --------------- ---------
  Age, years         57.78 (13.95)   61.26 (12.33)   0.013
  Sex                                                0.164
    Male             64.3 (115)      71.5 (128)      
    Female           35.7 (64)       28.5 (51)       
  Weight, kg         66.0 (20.0)     73.0 (24.5)     0.003
  Child-Pugh score                                   0.138
    Grade A          51.4 (92)       67.0 (120)      
    Grade B          7.3 (13)        4.4 (8)         
    Grade C          0 (0)           0.6 (1)         
  TNM Stage                                          \<0.001
    Stage I          35.8 (64)       57.2 (103)      
    Stage II         26.8 (48)       18.9 (34)       
    Stage III        30.2 (54)       15.6 (28)       
    Stage IV         1.1 (2)         1.1 (2)         
  Residual tumor                                     0.650
    R0               88.3 (158)      88.3 (159)      
    R1               3.4 (6)         4.5 (8)         
    R2               0 (0)           0.6 (1)         
    Rx               6.7 (12)        4.5 (8)         
  Edmondson grade                                    0.026
    G1               10.1 (18)       19.6 (35)       
    G2               45.8 (82)       49.7 (89)       
    G3               38.0 (68)       28.5 (51)       
    G4               3.9 (7)         2.2 (4)         

Data are presented as the mean ± SD, median and interquartile range or n%(n). *NT5DC2*-High, n=179. *NT5DC2*-Low, n=179. TCGA, The Cancer Genome Atlas.

###### 

Cox Proportional Hazards regression models for overall survival in The Cancer Genome Atlas liver cancer cohort (n=359).

                    Univariate            Multivariate                         
  ----------------- --------------------- -------------- --------------------- ---------
  Age, years        1.012 (0.998-1.026)   0.109                                
  Male              0.841 (0.585-1.210)   0.351                                
  *NT5DC2*/1,000    2.227 (1.369-3.625)   0.001          1.695 (1.016-1.727)   0.043
  TNM stage         1.512 (1.284-1.781)   \<0.001        1.460 (1.235-1.727)   \<0.001
  Edmondson grade   1.081 (0.852-1.372)   0.522                                

*NT5DC2*/1,000, *NT5DC2* per 1,000 units; HR, hazard ratio.

###### 

Cox Proportional Hazards regression model for relapse-free survival in The Cancer Genome Atlas liver cancer cohort (n=359).

                    Univariate            Multivariate                         
  ----------------- --------------------- -------------- --------------------- ---------
  Age, years        0.996 (0.984-1.008)   0.481                                
  Male              1.056 (0.761-1.466)   0.744                                
  *NT5DC2*/1000     2.360 (1.547-3.599)   \<0.001        1.780 (1.143-2.772)   0.011
  TNM stage         1.515 (1.312-1.750)   \<0.001        1.444 (1.242-1.678)   \<0.001
  Edmondson grade   1.096 (0.892-1.348)   0.382                                

*NT5DC2*/1,000, *NT5DC2* per 1,000 units; HR, hazard ratio.

###### 

Baseline data of PUMCH dataset (n=134).

  Characteristic                                             *NT5DC2*-High    *NT5DC2*-Low    P-value
  ---------------------------------------------------------- ---------------- --------------- ---------
  Age^[a](#tfn5-ol-0-0-11931){ref-type="table-fn"}^, years   55.27±11.44      57.93±10.52     0.164
  Sex                                                                                         0.084
    Male                                                     86.6 (58)        73.1 (49)       
    Female                                                   13.4 (9)         26.9 (18)       
  HBsAg, % positive                                          79.1 (53)        73.1 (49)       0.544
  Anti-HCV, % positive                                       9.0 (6)          9.0 (6)         1.000
  AST, U/l                                                   37.0 (37.5)      36.00 (25.5)    0.140
  ALT, U/l                                                   39.0 (36.0)      29.00 (29.2)    0.010
  GGT, U/l                                                   69.0 (98.5)      55.00 (59.5)    0.015
  ALP, U/l                                                   76.0 (43.0)      78.00 (49.5)    0.478
  AFP, ng/ml                                                 176.5 (2019.0)   30.00 (481.9)   0.063
  CA19-9, U/ml                                               24.2 (40.85)     22.00 (23.65)   \<0.001
  Edmondson grade                                                                             0.777
    G1                                                       23.9 (17)        26.8 (18)       
    G2                                                       62.7 (42)        61.2 (41)       
    G3                                                       27.2 (6)         7.5 (5)         
    G4                                                       4.3 (1)          0 (0)           
  TNM Stage                                                                                   0.732
    I                                                        59.7 (40)        55.2 (37)       
    II                                                       13.4 (9)         11.9 (8)        
    III                                                      25.4 (17)        28.4 (19)       
    IV                                                       1.5 (1)          4.5 (3)         

Data are presented as the mean ± SD, median and interquartile range or n%(n).

Results of Kolmogorov-Smirnov test for normality and F-test for equality of two variances P\>0.05. *NT5DC2*-High, n=67. *NT5DC2*-Low, n=67.

###### 

Cox Proportional Hazards regression model of overall survival in the Peking Union Medical College Hospital cohort (n=134).

                Univariate            Multivariate                         
  ------------- --------------------- -------------- --------------------- ---------
  Age, years    0.995 (0.973-1.019)   0.710                                
  Male          1.221 (0.625-2.384)   0.559                                
  *NT5DC2*/10   1.185 (1.064-1.320)   0.002          1.219 (1.090-1.364)   \<0.001
  AFP/1000      1.017 (1.007-1.026)   \<0.001        1.008 (0.998-1.018)   0.136
  TNM stage     1.703 (1.338-2.168)   \<0.001        1.830 (1.409-2.377)   \<0.001
  HBsAg         1.245 (0.720-2.154)   0.433                                

*NT5DC2*/10, *NT5DC2* per 10 units; AFP/1,000, AFP per 1,000 units; HBsAg, surface antigen of the hepatitis B virus.
